Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 964 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Airway Disease Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 14, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)

NCT01099410
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fiberoptic bronchoscopy, blood draw, intravenous catheter
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 14, 2026, 11:46 PM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

NCT01321463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PH-797804, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 14, 2026, 11:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039
View directory record Official record
Conditions
Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 14, 2026, 11:46 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 14, 2026, 11:46 PM EDT
Terminated No phase listed Observational

Evaluating Quality of Life for Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation

NCT00675376
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Transplantation
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 67 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Nursing-Driven Primary Palliative Care for Urban-Dwelling African Americans With Chronic Lung Disease

NCT05611125
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Telehealth Integrated Primary Care (TIPC)
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 14, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)

NCT04179981
View directory record Official record
Conditions
Sleep Apnea Syndrome, Obstructive Sleep Apnea, COPD, Overlap Syndrome, Quality of Life, Neurocognitive Function, Sleepiness, Elderly, Positive Airway Pressure
Interventions
Positive airway pressure, Conservative care (control arm)
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine Pulmonary Safety in Patients With COPD

NCT00889837
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled Loxapine, Inhaled Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
40 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 14, 2026, 11:46 PM EDT
Recruiting No phase listed Observational

STRIVE Post-Market Registry Study

NCT04302272
View directory record Official record
Conditions
Emphysema
Interventions
Spiration Valve System (SVS)
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Phoenix, Arizona • Mountain View, California • Coral Gables, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Azithromycin Treatment for the Airway Microbiome in Asthma

NCT03736629
View directory record Official record
Conditions
Asthma Chronic
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 14, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling

NCT05399056
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Telephonic Peer Coaching, Storytelling
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
40 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

NCT01697696
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
NVA237, Long-acting beta 2-agonist (LABA), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
61
States / cities
Gulf Shores, Alabama • Mobile, Alabama • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 14, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lung Tissue Research Consortium

NCT02988388
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Interventions
Lung biopsy/lobectomy
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00808288
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions
PF- 00610355, Placebo, Salmeterol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 14, 2026, 11:46 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

NCT07780669
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK5784283, Placebo, Standard of care
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Doral, Florida • Lake Charles, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00909779
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
73
States / cities
Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 14, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 1)

NCT03581227
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CAPTURE Tool
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 80 Years
Enrollment
4,679 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 14, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

NCT00970268
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 14, 2026, 11:46 PM EDT
Terminated Not applicable Interventional

Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure

NCT03353064
View directory record Official record
Conditions
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Obesity Hypoventilation Syndrome, Sleep Disordered Breathing, Neuromuscular Diseases
Interventions
Vivify, EMS
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 14, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 11:46 PM EDT